Patent · US Expired

Recombinant human anti-Lewis Y antibodies

US5874060A · kind A · utility

19Cited by
2References
7Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 20, 1997
Grant dateFeb 23, 1999
Priority date
Expiry dateMay 20, 2017

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2319/00
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

The invention provides for the production of several humanized murine antibodies specific for the antigen Lewis Y, which is recognized by the murine antibody Lewis Y. The Lewis Y antigen is expressed in normal tissues but the level of expression is higher in certain tumor types so that the antigen can be used as a marker for cells of some breast, colon, gastric, esophageal, pancreatic, duodenal, lung, bladder and renal carcinomas and gastric and islet cell neuroendocrine tumors. The invention also provides for numerous polynucleotide encoding humanized Lewis Y specific antibodies, expression vectors for producing humanized Lewis Y specific antibodies, and host cells for the recombinant production of the humanized antibodies. The invention also provides methods for detecting cancerous cells (in vitro and in vivo) using humanized Lewis Y specific antibodies. Additionally, the invention provides methods of treating cancer using humanized Lewis Y specific antibodies.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.